These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 24814888)

  • 21. Anti-angiogenic activity of a new andrographolide derivative in zebrafish and HUVECs.
    Li J; Peng Y; Li S; Sun Y; Chan JY; Cui G; Wang D; Zhou GC; Lee SM
    Eur J Pharmacol; 2016 Oct; 789():344-353. PubMed ID: 27471159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity.
    Bagli E; Stefaniotou M; Morbidelli L; Ziche M; Psillas K; Murphy C; Fotsis T
    Cancer Res; 2004 Nov; 64(21):7936-46. PubMed ID: 15520200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway.
    Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ
    Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-angiogenic activity and mechanism of kaurane diterpenoids from Wedelia chinensis.
    Huang W; Liang Y; Wang J; Li G; Wang G; Li Y; Chung HY
    Phytomedicine; 2016 Mar; 23(3):283-92. PubMed ID: 26969382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo.
    Rastelli L; Valentino ML; Minderman MC; Landin J; Malyankar UM; Lescoe MK; Kitson R; Brunson K; Souan L; Forenza S; Goldfarb RH; Rabbani SA
    Int J Oncol; 2011 Aug; 39(2):401-8. PubMed ID: 21567086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Curcumin inhibits angiogenesis and improves defective hematopoiesis induced by tumor-derived VEGF in tumor model through modulating VEGF-VEGFR2 signaling pathway.
    Fu Z; Chen X; Guan S; Yan Y; Lin H; Hua ZC
    Oncotarget; 2015 Aug; 6(23):19469-82. PubMed ID: 26254223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AGS-30, an andrographolide derivative, suppresses tumor angiogenesis and growth in vitro and in vivo.
    Li J; Li F; Tang F; Zhang J; Li R; Sheng D; Lee SM; Zhou GC; Leung GP
    Biochem Pharmacol; 2020 Jan; 171():113694. PubMed ID: 31706845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.
    Li T; Liu X; Shen Q; Yang W; Huo Z; Liu Q; Jiao H; Chen J
    Oncotarget; 2016 May; 7(18):26580-92. PubMed ID: 27058891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling.
    Gao J; Hu H; Wang X
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1007-1015. PubMed ID: 30887179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Raddeanin A, a triterpenoid saponin isolated from Anemone raddeana, suppresses the angiogenesis and growth of human colorectal tumor by inhibiting VEGFR2 signaling.
    Guan YY; Liu HJ; Luan X; Xu JR; Lu Q; Liu YR; Gao YG; Zhao M; Chen HZ; Fang C
    Phytomedicine; 2015 Jan; 22(1):103-10. PubMed ID: 25636878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activating CD137 Signaling Promotes Sprouting Angiogenesis via Increased VEGFA Secretion and the VEGFR2/Akt/eNOS Pathway.
    Li B; Zhang Y; Yin R; Zhong W; Chen R; Yan J
    Mediators Inflamm; 2020; 2020():1649453. PubMed ID: 33162828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The anti-angiogenic action of 2-deoxyglucose involves attenuation of VEGFR2 signaling and MMP-2 expression in HUVECs.
    Chuang IC; Yang CM; Song TY; Yang NC; Hu ML
    Life Sci; 2015 Oct; 139():52-61. PubMed ID: 26285173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclic adenosine monophosphate-response element-binding protein mediates the proangiogenic or proinflammatory activity of gremlin.
    Corsini M; Moroni E; Ravelli C; Andrés G; Grillo E; Ali IH; Brazil DP; Presta M; Mitola S
    Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):136-45. PubMed ID: 24233491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel compound T7 (N-{4'-[(1E)-N-hydroxyethanimidoyl]-3',5,6-trimethoxybiphenyl-3-yl}-N'-[4-(3-morpholin-4-ylpropoxy)phenyl]urea) screened by tissue angiogenesis model and its activity evaluation on anti-angiogenesis.
    Dai B; Qi J; Liu R; Zhang J; Zhan Y; Zhang Y
    Phytomedicine; 2014 Oct; 21(12):1675-83. PubMed ID: 25442276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Xia Y; Song X; Li D; Ye T; Xu Y; Lin H; Meng N; Li G; Deng S; Zhang S; Liu L; Zhu Y; Zeng J; Lei Q; Pan Y; Wei Y; Zhao Y; Yu L
    Sci Rep; 2014 Aug; 4():6031. PubMed ID: 25112436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of vascular endothelial growth factor-induced angiogenesis by scopoletin through interrupting the autophosphorylation of VEGF receptor 2 and its downstream signaling pathways.
    Pan R; Dai Y; Gao XH; Lu D; Xia YF
    Vascul Pharmacol; 2011; 54(1-2):18-28. PubMed ID: 21078410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.